SEC Filing Analysis: GILEAD SCIENCES, INC. (GILD)

Executive Summary

• Trading Significance: Low
• Key Takeaway: The Chairman & CEO, Daniel O'Day, conducted a minor, pre-planned sale of common stock totaling approximately $1.27 million.
• Market Impact: The transaction is immaterial, representing a negligible fraction of the company's market capitalization and the insider's total holdings.

Company Information

Field	Value
Company	GILEAD SCIENCES, INC.
Ticker Symbol	GILD
CIK	0000882095
Industry	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)

Insider Information

Field	Value
Name	O'Day Daniel Patrick
CIK	0001638643
Title/Position	Chairman & CEO
Relationship	Director, Officer

Transaction Details

Field	Value
Form Type	4
Transaction Date	2025-11-28
Transaction Code	S (Sale)
Security Type	Common Stock
Shares Involved	10,000
Price Per Share	~$126.55 (Weighted Average)
Total Value	$1,265,544
Shares Owned After	571,203
Ownership Type	Direct

Financial Impact Assessment

Transaction Materiality

Metric	Value
Transaction Value	$1,265,544
% of Market Cap	0.0008%
Shares Transacted	10,000
% of Shares Outstanding	0.0008%
Post-Transaction Ownership	571,203 shares (0.046% of outstanding)
Materiality Assessment	Low

Impact Evaluation

• Market Cap Context: For a mega-cap company like Gilead with a market capitalization of $155.11 billion, a $1.27 million transaction is considered routine and has no market-moving significance.
• Ownership Concentration: The sale represents a very small portion (~1.7%) of the insider's direct holdings, indicating this is not a significant liquidation of their position. The insider's ownership remains minimal relative to total shares outstanding.

Additional Context

Special Circumstances

• The filing explicitly states the sale was made pursuant to a Rule 10b5-1 trading plan adopted on February 28, 2025. This indicates the sale was pre-scheduled and not based on any immediate, non-public information.